Uric Acid Nephropathy Workup

1. Conger JD. Acute uric acid nephropathy. Med Clin North Am. 1990 Jul. 74(4):859-71. [QxMD MEDLINE Link].

2. Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014 Jun. 29 (6):999-1008. [QxMD MEDLINE Link].

3. Ejaz AA, Johnson RJ, Shimada M, Mohandas R, Alquadan KF, Beaver TM, et al. The Role of Uric Acid in Acute Kidney Injury. Nephron. 2019. 142 (4):275-283. [QxMD MEDLINE Link]. [Full Text].

4. Dykman D, Simon EE. Hyperuricemia and uric acid nephropathy. Arch Intern Med. 1987 Jul. 147(7):1341-5. [QxMD MEDLINE Link].

5. Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease--review of a non-disease. Nephrol Dial Transplant. 1997 Sep. 12(9):1832-8. [QxMD MEDLINE Link]. [Full Text].

6. Berger L, Yü TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975 Nov. 59 (5):605-13. [QxMD MEDLINE Link].

7. Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease?. J Hypertens. 2008 Nov. 26(11):2085-92. [QxMD MEDLINE Link].

8. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015 Sep. 33 (9):1729-41; discussion 1741. [QxMD MEDLINE Link].

9. Kim Y, Shin S, Kim K, Choi S, Lee K. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease. J Rheumatol. 2015 Nov. 42 (11):2143-8. [QxMD MEDLINE Link].

10. Avram Z, Krishnan E. Hyperuricaemia--where nephrology meets rheumatology. Rheumatology (Oxford). 2008 Jul. 47(7):960-4. [QxMD MEDLINE Link].

11. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004 Oct. 44(4):642-50. [QxMD MEDLINE Link].

12. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008 Jul. 75 Suppl 5:S13-6. [QxMD MEDLINE Link]. [Full Text].

13. Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012. 36(4):324-31. [QxMD MEDLINE Link].

14. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?. J Am Soc Nephrol. 2005 Jul. 16(7):1909-19. [QxMD MEDLINE Link]. [Full Text].

15. Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005. 147:35-46. [QxMD MEDLINE Link].

16. Lin JL, Yu CC, Lin-Tan DT, et al. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int. 2001 Jul. 60(1):266-71. [QxMD MEDLINE Link]. [Full Text].

17. Kim YJ, Kim CH, Sung EJ, Kim SR, Shin HC, Jung WJ. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism. 2013 Jun. 62(6):808-13. [QxMD MEDLINE Link].

18. Emami-Naini A, Eshraghi A, Shahidi S, Mortazavi M, Seyrafian S, Roomizadeh P, et al. Metabolic evaluation in patients with nephrolithiasis: A report from Isfahan, Iran. Adv Biomed Res. 2012. 1:65. [QxMD MEDLINE Link]. [Full Text].

19. Bainbridge SA, Deng JS, Roberts JM. Increased xanthine oxidase in the skin of preeclamptic women. Reprod Sci. 2009 Feb 5. [QxMD MEDLINE Link].

20. Roncal-Jimenez C, García-Trabanino R, Barregard L, Lanaspa MA, Wesseling C, Harra T, et al. Heat Stress Nephropathy From Exercise-Induced Uric Acid Crystalluria: A Perspective on Mesoamerican Nephropathy. Am J Kidney Dis. 2015 Oct 5. [QxMD MEDLINE Link].

21. Mukherjee E, Mukherji D, Jayawardene SA, et al. Tumor lysis syndrome and acute renal failure--an increasing spectrum of presentations. Clin Nephrol. 2007 Sep. 68(3):186-9. [QxMD MEDLINE Link].

22. Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008 Dec. 70(6):523-6. [QxMD MEDLINE Link].

23. U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: ELITEK (rasburicase). FDA.gov. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103946s5101lbl.pdf. 9/2017 (revised); Accessed: April 6, 2018.

24. Nauffal M, Redd R, Ni J, Stone RM, DeAngelo DJ, McDonnell AM. Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract. 2019 Sep. 25 (6):1349-1356. [QxMD MEDLINE Link].

25. Kishimoto K, Kobayashi R, Hori D, Sano H, Suzuki D, Kobayashi K. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017 Oct. 37 (10):5845-5849. [QxMD MEDLINE Link].

26. Yasu T, Kobayashi S, Horii M, Kurokawa Y. The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphoma
. Int J Clin Pharmacol Ther. 2016 Dec. 54 (12):1009-1012. [QxMD MEDLINE Link].

27. Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016 Oct. 21 (5):996-1003. [QxMD MEDLINE Link].

28. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29. 378 (13):1200-1210. [QxMD MEDLINE Link].

29. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. NCCN,org. Available at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Version 4.2019 — June 18, 2019; Accessed: September 10, 2019.

30. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005 Jul. 18(3):275-9. [QxMD MEDLINE Link]. [Full Text].

31. Hochberg J, Cairo MS. Rasburicase: future directions in tumor lysis management. Expert Opin Biol Ther. 2008 Oct. 8(10):1595-604. [QxMD MEDLINE Link].

Mark T Fahlen, MD Private Practice, Mark T Fahlen, MD, Inc

Mark T Fahlen, MD is a member of the following medical societies: American College of Physicians, Renal Physicians Association

Disclosure: Nothing to disclose.

Mahendra Agraharkar, MD, MBBS, FACP, FASN Clinical Associate Professor of Medicine, Baylor College of Medicine; President and CEO, Space City Associates of Nephrology

Mahendra Agraharkar, MD, MBBS, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Eleanor Lederer, MD, FASN is a member of the following medical societies: American Association for the Advancement of Science, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Society of Nephrology<br/>Received income in an amount equal to or greater than $250 from: Healthcare Quality Strategies, Inc.

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article